Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu
Novartis and Alnylam Pharmaceuticals, Inc. announced that they have formed a new collaboration to develop RNAi therapeutics for pandemic flu. This collaboration is in addition to the collaboration formed by the two companies in September 2005, and significantly reinforces the development program for pandemic flu announced by Alnylam in December 2005. In the newly formed collaboration, Alnylam and Novartis will advance RNAi therapeutics for pandemic flu to initial clinical testing and, if successful, regulatory approval. This new alliance leverages Alnylam's expertise in RNAi and Novartis' capabilities and experience in bringing innovative therapeutics to patients. Financial terms were not disclosed.
Most read news
Organizations
Other news from the department business & finance
![Newsletter](https://img.chemie.de/assets/awportal/images/newsletter.png)
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.